TrialArthritis research & therapy2022

Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE).

Seerapani Gopaluni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.